Search Results

GSK461364 25 mg  | 99.00%

TargetMol

GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.

More Information Supplier Page

(R)-(-)-Gossypol acetic acid 5 mg  | 96.73%

TargetMol

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 2.

More Information Supplier Page

(R)-(-)-Gossypol acetic acid 25 mg  | 96.73%

TargetMol

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 2.

More Information Supplier Page

TCID 50 mg  | 97.16%

TargetMol

TCID(IC50=0.6 μM) is a DUB inhibitor of ubiquitin C-terminal hydrolase L3. It has the 125-fold selectivity to L1.

More Information Supplier Page

TCID 5 mg  | 97.16%

TargetMol

TCID(IC50=0.6 μM) is a DUB inhibitor of ubiquitin C-terminal hydrolase L3. It has the 125-fold selectivity to L1.

More Information Supplier Page

Fluocinonide 200 mg  | 100.00%

TargetMol

Fluocinonide (Vanos) is an effective glucocorticoid steroid, utilized in the treatment as the skin disorders anti-inflammatory agent.

More Information Supplier Page

BML-190 200 mg  | 99.51%

TargetMol

BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.

More Information Supplier Page